Curis, Inc. (CRIS) Analysts See $-0.41 EPS

July 11, 2018 - By Kristin Houston

Curis, Inc. (NASDAQ:CRIS) LogoInvestors sentiment decreased to 0.86 in Q1 2018. Its down 0.73, from 1.59 in 2017Q4. It fall, as 10 investors sold Curis, Inc. shares while 25 reduced holdings. 14 funds opened positions while 16 raised stakes. 62.11 million shares or 17.79% less from 75.55 million shares in 2017Q4 were reported.
Alliancebernstein Lp invested 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). 1.99M were reported by State Street. California State Teachers Retirement Sys reported 208,456 shares or 0% of all its holdings. Barclays Public Ltd Llc owns 0% invested in Curis, Inc. (NASDAQ:CRIS) for 29,917 shares. Bb&T Lc holds 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS) for 96,522 shares. Principal Group stated it has 17,990 shares or 0% of all its holdings. Fincl Bank Of America De holds 0% in Curis, Inc. (NASDAQ:CRIS) or 91,122 shares. Meridian Invest Counsel, California-based fund reported 10,000 shares. Germany-based Deutsche State Bank Ag has invested 0% in Curis, Inc. (NASDAQ:CRIS). Rhumbline Advisers reported 107,374 shares. Citigroup, New York-based fund reported 17,529 shares. Creative Planning has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 21,000 shares. Drw Secs Ltd Liability Com owns 50,000 shares for 0% of their portfolio. Wells Fargo Mn stated it has 0% of its portfolio in Curis, Inc. (NASDAQ:CRIS). 834,551 were reported by Sio Capital Mgmt Ltd Co.

Analysts expect Curis, Inc. (NASDAQ:CRIS) to report $-0.41 EPS on August, 2.They anticipate $0.09 EPS change or 18.00 % from last quarter’s $-0.5 EPS. After having $-0.35 EPS previously, Curis, Inc.’s analysts see 17.14 % EPS growth. The stock increased 3.37% or $0.06 during the last trading session, reaching $1.84. About 143,273 shares traded. Curis, Inc. (NASDAQ:CRIS) has declined 73.52% since July 12, 2017 and is downtrending. It has underperformed by 86.09% the S&P500.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Among 2 analysts covering Curis (NASDAQ:CRIS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Curis had 2 analyst reports since May 7, 2018 according to SRatingsIntel. The firm has “Outperform” rating by Robert W. Baird given on Monday, May 7. The firm has “Buy” rating given on Thursday, May 31 by SunTrust.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company has market cap of $60.95 million. The firm develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It currently has negative earnings. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis.

More recent Curis, Inc. (NASDAQ:CRIS) news were published by: which released: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018. Also published the news titled: “Benzinga’s Daily Biotech Pulse: Titan’s Parkinson’s Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32 …” on July 03, 2018.‘s news article titled: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” with publication date: June 29, 2018 was also an interesting one.

Curis, Inc. (NASDAQ:CRIS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.